Equities

HLS Therapeutics Inc

HLS Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CAD)4.73
  • Today's Change-0.04 / -0.84%
  • Shares traded1.20k
  • 1 Year change-12.41%
  • Beta1.0965
Data delayed at least 15 minutes, as of May 07 2024 18:36 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

HLS Therapeutics Inc. is a pharmaceutical company. It is focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Insite, MyCare Psychiatry, PERSERIS, Trinomia and Vascepa. Its lead product is Clozaril, which is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Trinomia product related to the treatment of cardiovascular disease.

  • Revenue in CAD (TTM)86.17m
  • Net income in CAD-37.61m
  • Incorporated2018
  • Employees91.00
  • Location
    HLS Therapeutics Inc10 Carlson Court, Suite 701ETOBICOKE M9W 6L2CanadaCAN
  • Phone+1 (647) 495-9000
  • Fax+1 (647) 495-9000
  • Websitehttps://www.hlstherapeutics.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Pineapple Express Cannabis Co0.001.23m48.65m--39.6133.5839.50--0.04420.04420.000.05210.00------165.84-141.47181.89---------116.53----0.00---30.45--3.56------
Petmed Express Inc369.68m-8.31m121.96m302.00--0.7851--0.3299-0.299-0.29913.305.381.657.38143.74895,761.60-3.7014.04-4.7217.1227.8029.54-2.258.211.64--0.00100.72-6.06-1.27-98.90-63.2649.567.14
CareRx Corp370.75m-5.41m138.80m1.44k--1.709.530.3744-0.097-0.0976.311.361.4913.3210.15---2.18-13.05-2.92-19.3628.2428.91-1.46-9.700.73270.56760.5455---2.8825.5484.27--14.34--
Marimed Inc203.07m-21.91m150.13m643.00--1.52--0.7393-0.043-0.0430.4090.24140.85323.6926.17231,101.10-9.19-13.42-10.88-17.5044.3649.18-10.77-14.830.84651.690.4395--10.8965.82-219.03--18.39--
HLS Therapeutics Inc86.17m-37.61m151.85m91.00--1.1425.221.76-1.17-1.172.674.170.27990.82716.80957,463.30-12.22-7.09-14.02-8.0987.9192.49-43.65-33.621.30-2.260.4728--2.610.5345-16.67---24.71--
High Tide Inc497.66m-35.87m239.21m----1.72--0.4807-0.4764-0.47646.571.751.9914.4169.05---14.80-23.58-19.80-31.0027.1529.68-7.45-15.740.68940.60440.318--36.66123.4845.22--7.54--
Data as of May 07 2024. Currency figures normalised to HLS Therapeutics Inc's reporting currency: Canadian Dollar CAD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.